Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant

Authors: Robert R. Redfield, Stanley C. Jordan, Stéphan Busque, Flavio Vincenti, E. Steve Woodle, Niraj M. Desai, Elaine F. Reed, Simon Tremblay, Andrea A. Zachary, Ashley Vo, Richard N. Formica, Thomas H. Schindler, Ha Tran, Caroline Looney, Candice Jamois, Cherie Green, Alyssa Morimoto, Richa Rajwanshi, Aaron Schroeder, Matthew D. Cascino, Paul Brunetta, Dominic Borie - American Journal of Transplantation 2019 cited by 79